Diabetic Macular Oedema
An Introduction to Diabetic Macular Oedema
The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies changed the standard of care for patients with diabetic macular oedema, however, the need for longer-acting medications and novel therapeutic targets still exist. Looking to the future, new treatments targeting multiple pathways are currently under investigation.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Diabetic Macular Oedema Content
Ramin Khoramnia, WOC 2020 – STAIRWAY Phase 2 Trial
Ramin Khoramnia (University Eye Clinic Heidelberg, Heidelberg, Germany) discusses imitations of current treatment options for neovascular age-related macular degeneration, gives an overview of faricimab, its dosing regimen and its mechanism of action and discusses the major efficacy and safety findings of the STAIRWAY study, which were presented at WOC 2020. 1. What are the limitations […]
Aditya Sudhalkar, EURETINA 2019 – Latest research on the use of intravitreal steroids in DME
We met up with Aditya Sudhalkar at EURETINA 2019 to discuss his latest research into treating patients with intravitreal dexamethasone and to learn about his experiences as a rising-star in the field. Support: The production of this video was supported by Allergan, who had no involvement with the development of the content. Filmed at the […]
Samantha Fraser-Bell, EURETINA 2019 – Results of the AUSSIDEX study
Samantha Fraser-Bell (University of Sydney) caught up with us to share the latest results of the AUSSIDEX study, and discuss the real-world impact on patients with DME. Questions: 1. What are the main challenges you face when treating patients with diabetic macular oedema? (0:04) 2. Tell us about your current research in this area (0:31) […]
David Pelayes, EURETINA 2019 – Treatment approaches to DME
David Pelayes (Professor of Ophthalmology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg, Germany) discusses the current limitations with treatment approaches to DME and the evolving use of OCT-A to predict the response a patient have to DEM treatment. Questions: 1. What recent advances in ophthalmology have had the biggest impact on your practice? 2. What are the […]
Steroids for Diabetic Macular Oedema – A Brief Review of the Data
European Ophthalmic Review. 2019:13(1):44-8 DOI: https://doi.org/10.17925/EO R.2019.13.1.44
Diabetic macular oedema (DMO) is a complication of diabetic retinopathy and is a leading cause of blindness in working-age adults in developed nations. In 2015, there were an estimated 415 million people with diabetes worldwide.1 This number is predicted to rise to 642 million by 2040.1 The prevalence of DMO is estimated to be up […]
Christina Vidinova, SOE 2019 – Meeting highlights
Christina Vidinova talks about her highlights from SOE 2019, including photoablation therapy, which has been under research for 20 years and imaging technologies in DME that can predict risk factors. Sessions for young ophthalmologists are important and gives them the opportunity to learn new skills. Filmed in partnership with the European Society of Ophthalmology (SOE) […]
Jean-François Korobelnik, AAO 2018 – Aflibercept and the APOLLON Study
Professor Jean-François Korobelnik joins us to discuss aflibercept and its effectiveness as a widely used and well-tolerated anti-vascular endothelial growth factor (VEGF) inhibitor. He also briefly describes the APOLLON study, looking at the real-life treatment, monitoring and outcomes of treatment in patients with diabetic macular edema in routine clinical practice. Questions: 1. What advantages does […]
The 0.19 mg Fluocinolone Acetonide Intravitreal Implant – A Review on its Use in Diabetic Macular Oedema from the Association for Research in Vision and Ophthalmology Annual Meeting 2018
European Ophthalmic Review. 2018;12(2):88–97 DOI: https://doi.org/10.17925/EOR.2018.12.2.88
Diabetic macular oedema (DMO) is a complication of diabetic retinopathy, a microvascular ocular complication of diabetes mellitus.1 The blood–retinal barrier (BRB) is a specialised structure, which tightly regulates, maintains and balances the levels of electrolytes, protein and fluid in the retinal tissues – a function that is central to the maintenance of normal visual acuity […]
Anti-VEGF Treatment in Chronic Persistent Diabetic Macular Oedema
European Ophthalmic Review. 2018;12(1):21–3 DOI: https://doi.org/10.17925/EOR.2018.12.1.21
Q. How prevalent is chronic persistent diabetic macular oedema following anti-vascular endothelial growth factor (VEGF) treatment? To determine the prevalence of chronic persistent diabetic macular oedema (cpDMO), one must first define what is meant by cpDMO. In a post hoc exploratory analysis by the Diabetic Retinopathy Clinical Research Network (DRCR.net), authors defined persistent DMO (pDMO) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!